Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

Asthma, Aspirin-Induced Clinical Trial

— Aspirin  

Official title:

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01597375
• Other study ID #: 2010P002961
• Status: Completed
• Phase: Phase 2
• Start date: August 31, 2012
• Est. completion date: December 14, 2016

Study information

• Verified date: September 2019
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are doing this research study to find out if giving a drug called prasugrel, which is used to prevent blood clots, can reduce reactions to aspirin in people with aspirin exacerbated respiratory disease (AERD), and to learn why taking aspirin every day can work as a treatment for people with AERD. People with AERD have symptoms of asthma, severe runny nose, polyps in the nose, and develop allergic reactions if they take medications like aspirin.

People with AERD can be desensitized to aspirin in order to be able to safely use it daily, but the investigators do not know if prasugrel may prevent reactions to aspirin and provide a safer way for people with AERD to tolerate aspirin.

The investigators also want to understand what is different about the cells and urine from subjects who have AERD, in comparison to subjects who have asthma but do not have AERD and subjects who have allergic rhinitis but do not have asthma. Lastly, the investigators want to understand how aspirin acts differently in subjects who have AERD, in comparison to subjects who have asthma but do not have AERD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: December 14, 2016
• Est. primary completion date: December 14, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria for Participants with AERD:

• History of physician-diagnosed asthma

• History of nasal polyposis

• History of at least one clinical reaction to oral aspirin or other nonselective COX inhibitor with features of both lower (cough, chest tightness, wheezing, dyspnea) and upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge) airway involvement.

• Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months).

• No current smoking, defined as no daily tobacco smoking for at least 6 months and not more than one instance of tobacco smoking in the last 3 months.

• Non-pregnant

• Only those individuals who would otherwise meet clinical qualifications for aspirin desensitization and treatment with high-dose aspirin will be considered for enrollment in the study.

Inclusion Criteria for Participants who are Aspirin Tolerant Asthmatics:

• History of physician-diagnosed asthma.

• No current nasal polyposis confirmed by nasal examination.

• No history of any adverse reaction to aspirin or a COX inhibitor.

• Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months).

• No current smoking

• Non-pregnant

Inclusion Criteria for Non Asthmatics with Allergic Rhinitis:

• No history of physician-diagnosed asthma.

• No current nasal polyposis confirmed by nasal examination.

• No history of any adverse reaction to aspirin or a COX inhibitor.

• No current smoking

• Non-pregnant

• Clinical history of symptoms consistent with allergic rhinitis and previously documented allergy to at least one environmental,immunoglobulin E (IgE) testing).

• Normal lung function (baseline FEV1 of 80% of predicted or better).

• A score of 4 or below on the Asthma Screening Questionnaire (33) and negative responses to asthma history questions

Exclusion Criteria for participants with AERD:

• Current breastfeeding

• History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs

• Hypersensitivity to montelukast or thienopyridines

• History of peptic ulcer disease or gastrointestinal bleed

• Current severe gastro-esophageal reflux disease (GERD), defined as patient currently requiring more than 2 total doses of medication per day to treat persistent symptoms: either more than 2 doses of any single medication type (antacid, proton pump inhibitor, or H2 receptor antagonist), or more than 2 types of medication per day to treat symptoms

• History of systemic or life-threatening respiratory reaction to aspirin requiring intubation or administration of adrenalin

• Current use of any oral beta blocker (due to the risk of bronchospasm associated with beta blockers).

• History of transient ischemic attack or stroke, or diabetes.

• Current presence of uncontrolled hypertension.

• History of hepatic impairment or alcoholism, or evidence of abnormal liver function at Screening Visit. Aspartate transaminase (AST) and alanine transaminase (ALT) levels may not exceed 1.5x the upper limit of normal at Screening Visit (AST may not exceed 52 IU/L, ALT may not exceed 78 IU/L).

Exclusion Criteria for Participants with Aspirin Tolerant Asthma and Non Asthmatics with Allergic Rhinitis:

• Current breastfeeding

• History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs

• Hypersensitivity to montelukast or thienopyridines

• History of peptic ulcer disease or gastrointestinal bleed

• Current severe GERD

• Current use of any oral beta blocker.

Related Conditions & MeSH terms

• Aspirin Exacerbated Asthma
• Asthma
• Asthma, Aspirin-Induced
• Respiration Disorders
• Respiratory Tract Diseases

Intervention

Drug:
• Placebo Oral Tablet
Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
• Prasugrel Oral Tablet
Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Locations

Country	Name	City	State
United States	Asthma Research Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Elliot Israel, MD	Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Baseline Differences in Platelet Chemistry in Subjects With AERD Compared to Controls	To determine if there are baseline differences in the percentages of activated platelets, platelet-leukocyte aggregates, or the plasma levels of soluble platelet products in subjects with AERD, compared to aspirin tolerant asthmatics (ATA) and non-asthmatic controls.	Evaluated at visit 1 (week 4)
Other	Effect of Prasugrel on Platelet Chemistry in Subjects With AERD During Aspirin Challenge.	To determine if treatment with prasugrel changes the baseline percentages of activated platelets or platelet-leukocyte aggregates or changes the plasma levels of soluble platelet products during clinical reaction to aspirin	Evaluated at visit 2 and 3 (week 8 and 14)
Primary	Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo	The PD2 is the provocative dose of aspirin that elicits an increase in nasal symptom score of 2 during an aspirin challenge. The PD2 is calculated by: inverse?log?_10 (((2-(PrevTNSS-BaselineTNSS))×(?log?_10 ProvocDose-?log?_10 PrevDose))/((MaxTNSS-BaselineTNSS)-(PrevTNSS-BaselineTNSS) )+(?log?_10 PrevDose))	Difference in PD2 (provocative dose of aspirin that elicits an increase in nasal symptom score of 2 during an aspirin challenge) between Visits 2 and 3 (weeks 8 and 14), calculated at visit 3
Primary	Change From Baseline Expression Levels of COX-2 Transcript and Protein in Peripheral Blood Leukocytes of Subjects With AERD After 8 Weeks of Treatment With Aspirin.	This study will compare this outcome within each participant between baseline (established at Visit 1, prior to initiation of prasugrel therapy) and at the completion of 8 weeks of aspirin therapy.	Evaluated at visits 1 and 4 (weeks 4 and 22)
Secondary	Difference in Participant's Provocative Dose of Aspirin When Pretreated With Prasugrel Versus Placebo	We will monitor the dose of aspirin at which the participant shows symptoms (increased discomfort, 15% drop in FEV1) during the aspirin challenge/desensitization. We will compare the provocative aspirin dose obtained from the aspirin challenge occurring after pretreatment with prasugrel to the dose obtained after pretreatment with placebo.	Evaluated at visits 2 and 3 (weeks 8 and 14)
Secondary	Change in Total Nasal Symptom Score(TNSS)From Baseline to Peak During Aspirin Challenge on Placebo Versus Prasugrel.	The primary outcome in Part 1 will be the maximum Total Nasal Symptom Score (TNSS) attained for subjects with AERD during the clinical reaction to aspirin challenge. The primary analysis will compare this outcome within each participant after treatment with prasugrel versus placebo. Nasal symptoms including congestion, rhinorrhea, runny nose, itchy nose, sneezing, itchy eyes, teary eyes, itchy ears/throat, and eye redness were assessed on a 0- to 5-point scale (0, none-5, very severe) in response to the provocative dose of aspirin during aspirin challenge/desensitization and summed together to generate the TNSS score (range 0-40).	Data obtained at visits 2 and 3 (weeks 8 and 14) and change calculated at visit 3
Secondary	Change in Urinary LTE4 During Aspirin Challenge on Placebo Versus Prasugrel	We will compare the participant's Leukotriene E4 (LTE4) obtained from the aspirin challenge done after pretreatment with prasugrel, the aspirin challenge done after pretreatment with placebo.	Change from visits 2 at visit 3 (weeks 8, 14), calculated and reported at visit 3
Secondary	Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Measurement After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks	We will note difference in the fractional exhaled nitric oxide (FeNO) obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment ( 650 mg oral aspirin tablet twice daily )	Evaluated at baseline and reported at 8 weeks
Secondary	Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Score After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks	We will note difference in the Asthma Control Questionnaire-7 (ACQ-7) score [ The ACQ has 7 questions on a 7-point scale (minimum score of 0=no impairment, maximum score of 6= maximum impairment)] obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment ( 650 mg oral aspirin tablet twice daily )	Evaluated at baseline and reported at 8 weeks
Secondary	Change From Baseline in Prostaglandin Metabolites (PGD-M) Measurement After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks	We will note difference in the Prostaglandin metabolites (PGD-M) measurement obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment ( 650 mg oral aspirin tablet twice daily )	Evaluated at baseline and reported at 8 weeks

External Links

•   Click here for more info.